In June of 2021 the Alzheimer’s drug, Aduhelm, was approved by the U.S. Food and Drug Administration (FDA). Aduhelm is a monoclonal antibody. It targets a specific protein in the brain that is thought to form plaques in the brains of Alzheimer’s patients, causing brain cells to atrophy and die.
Category: Doctors & Hospitals
Wednesday Links
- Less developed countries discover how to provide economical mental health care: use non-specialists.
- How reliable are patient online reviews at detecting physician and hospital quality? Not good.
- Is Obamacare’s free preventive medicine mandate unconstitutional? (WSJ)
- 94% of US residents have gotten Covid.
Pharmacist: That Prescription Will Cost You $3.5 Million!
A new record has been set for the highest price medication. The newly approved hemophilia drug Hemgenix.
A Hospital Stay (but in Your Own Home)
Years ago, I worked in a long-term acute care hospital. We employed social workers whose job was discharge planning. They charted out where to move patients once they had been treated by our hospital. This process was started before patients were admitted. Patients with no clear path to move elsewhere were not admitted. Our average length of stay was in excess of 30 days. At that time our type of facility was PPS exempt and cost reimbursed based on a TEFRA limit (see p. 71 for more information).